SDx Showcases Autopsy-Confirmed Results for DISCERN™ Alzheimer’s Test and Physicians’ Assessment of the Clinical Utility of DISCERN at BRAINWeek 2023

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce that with the acceptance of an oral presentation of “Autopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer's Disease Even in the Presence of Co-Morbid Pathologies” and a poster presentation of “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease (AD)," the Company will participate at BRAINWeek 2023, September 6-8, 2023, Las Vegas.

“Upon autopsy, over 50% of people with AD have additional co-morbid pathologies of dementia, such as multi-infarct dementia, Parkinson’s disease or Frontal Lobe Dementia,” says Frank Amato, CEO and president, SDx. “At BRAINWeek, we will present specific data evaluating the ability of the Morphometric Imaging (MI) assay in DISCERN™ to accurately identify AD in people diagnosed with dementia, even in the presence of other co-morbid pathologies at autopsy. Additionally, our poster entitled “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose AD” will demonstrate the important autopsy-validated clinical study of the DISCERN test and its unparalleled contribution to accurately inform physician decision-making. These results show significantly higher clinician confidence in an AD diagnosis, especially in those recently diagnosed with dementia.”

Read the full release here: http://tinyurl.com/5akd7pc6